How many shares did ADMA repurchase in Q2 2026 and year-to-date?

ADMA repurchased approximately 7.1 million shares in Q2 2026 and 13.8 million shares year-to-date through June 30, 2026. This represents 5.3% of the company's outstanding common stock.

How is ADMA funding its 2026 share repurchase program?

The company is funding repurchases through organically generated operating cash flow. ADMA completed an accelerated share repurchase (ASR) program in Q2 2026, supplementing open-market purchases under Rule 10b-18.

What is ADMA's 2026 share repurchase target and current status?

ADMA has announced a $200 million or more share repurchase target for 2026 and stated it is on track to complete this target. The company remains active with buybacks and has maintained financial flexibility for other strategic investments.

How did the share buybacks impact ADMA's earnings per share in Q2 2026?

GAAP basic EPS grew 17% year-over-year ($0.17 in Q2 2026 vs. $0.14 in Q2 2025), outpacing the 11% increase in GAAP net income. This outperformance reflects earnings accretion from the reduced share count due to repurchases.

Was this buyback program previously authorized or is this a new authorization?

The filing states ADMA repurchased shares 'under its previously authorized share repurchase program,' indicating this is an execution of an existing authorization. The filing does not disclose a new or expanded authorization amount.

ADMA 8-K Filed 2026-08-05 Execution disclosure

ADMA Biologics repurchased 7.1M shares in Q2 2026 under buyback program

Year-to-date 13.8M shares repurchased; company on track for $200M+ 2026 target through operating cash flow and ASR program.

Shares repurchased7.1M

MechanismRule 10b-18 open-market purcha

What the filing says

ADMA Biologics repurchased approximately 7.1 million shares of common stock during the second quarter of 2026 under its previously authorized share repurchase program. Year-to-date through June 30, 2026, the company has repurchased a total of approximately 13.8 million shares, representing 5.3% of outstanding common stock. These repurchases were funded through organically generated operating cash flow and included the completion of an accelerated share repurchase (ASR) program in the second quarter.

The company stated it remains active with share repurchases and is on track to complete its previously announced $200 million or more 2026 share repurchase target. Management emphasized that despite the buyback activity, ADMA maintained substantial financial flexibility to support commercial expansion, manufacturing initiatives, and pipeline development, demonstrating disciplined capital allocation aimed at enhancing stockholder value.

During the second quarter, ADMA repurchased approximately 7.1 million shares of common stock under its previously authorized share repurchase program. Year-to-date total stock repurchases through June 30, 2026 were approximately 13.8 million shares, amounting to 5.3% of the Company's common stock outstanding. In addition to the Company's accelerated share repurchase (ASR) program completed in the second quarter, ADMA's stock repurchases were funded through organically generated operating cash flow, while the Company maintained substantial financial flexibility to support commercial expansion, manufacturing initiatives and pipeline development. The Company remains active with share repurchases and is on track to complete its previously stated $200 million or more 2026 share repurchase target. — ADMA BIOLOGICS, INC. 8-K filing · View on SEC EDGAR →

What this means

ADMA's Q2 2026 buyback execution reflects ongoing capital allocation to return cash to shareholders while maintaining operational flexibility. The 13.8 million shares repurchased year-to-date (5.3% of outstanding) contributed to an 18% increase in basic EPS ($0.17 in Q2 2026 vs. $0.14 in Q2 2025), despite net income rising only 11%, demonstrating the accretion effect of share count reduction. The company's confidence in completing a $200+ million 2026 buyback target—funded from organic operating cash flow—suggests management views the stock as attractively valued relative to the company's ASCENIV-driven growth trajectory and projected 2026 financial performance. This disciplined approach balances shareholder returns with investment in commercial expansion and pipeline development.

Frequently asked questions

How many shares did ADMA repurchase in Q2 2026 and year-to-date?: ADMA repurchased approximately 7.1 million shares in Q2 2026 and 13.8 million shares year-to-date through June 30, 2026. This represents 5.3% of the company's outstanding common stock.
How is ADMA funding its 2026 share repurchase program?: The company is funding repurchases through organically generated operating cash flow. ADMA completed an accelerated share repurchase (ASR) program in Q2 2026, supplementing open-market purchases under Rule 10b-18.
What is ADMA's 2026 share repurchase target and current status?: ADMA has announced a $200 million or more share repurchase target for 2026 and stated it is on track to complete this target. The company remains active with buybacks and has maintained financial flexibility for other strategic investments.
How did the share buybacks impact ADMA's earnings per share in Q2 2026?: GAAP basic EPS grew 17% year-over-year ($0.17 in Q2 2026 vs. $0.14 in Q2 2025), outpacing the 11% increase in GAAP net income. This outperformance reflects earnings accretion from the reduced share count due to repurchases.
Was this buyback program previously authorized or is this a new authorization?: The filing states ADMA repurchased shares 'under its previously authorized share repurchase program,' indicating this is an execution of an existing authorization. The filing does not disclose a new or expanded authorization amount.
How does ADMA balance buybacks with other capital needs?: Management emphasized that despite aggressive share repurchases, the company maintained 'substantial financial flexibility' to support commercial expansion, manufacturing initiatives, and SG-001 pipeline development. The company also raised $125 million under a new JPM revolving facility during the period, further enhancing liquidity.

execution asr rule-10b-18 biopharmaceutical capital-allocation mid-cap

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.